Table 4.
Summary of outcomes after in vivo transfer of CML-14736 into histocompatible miniature swine
| Animal | Age, mo | Coancestry | Pretreatment | Immunosuppression | Tumor source | Outcome |
|---|---|---|---|---|---|---|
| 16354 (DD2, 10) | 3 | 0.94 | None | None | Cultured cells: IV, SC | No growth |
| 16354 (DD2, 10) | 3 | 0.94 | None | None | Primary tissue: SC | No growth |
| 16524 (DD4, G9) | 1.5 | 0.87 | 500 cGy TBI | None | Cultured cells: IV, SC | Tumor growth at SC sites and in lung |
| 16523 (DD4, G9) | 1.5 | 0.87 | 300 cGy TBI | None | Cultured cells: IV, SC | Tumor growth at SC sites only |
| 16526 (DD4, G9) | 3 | 0.87 | 300 cGy TBI | None | Cultured cells: IV, SC | Tumor growth at SC sites only |
| 16526 (DD4, G9) | 3 | 0.87 | 300 cGy TBI | None | Passaged cells: SC | Tumor growth |
| 16527 (DD4, G9) | 4 | 0.87 | 100 cGy TBI | None | Cultured cells: IV, SC | No growth |
| 16527 (DD4, G9) | 4 | 0.87 | 100 cGy TBI | None | Passaged cells: SC | No growth |
| 16525 (DD4, G9) | 2 | 0.87 | None | CyA (30 d) | Cultured cells: IV, SC | No growth |
| 16525 (DD4, G9) | 2 | 0.87 | None | CyA (30 d) | Passaged cells: SC | No growth |
IV indicates intravenous; and SC, subcutaenous.